Imiquimod
- Generic Name
- Imiquimod
- Brand Names
- Aldara, Vyloma, Zyclara
- Drug Type
- Small Molecule
- Chemical Formula
- C14H16N4
- CAS Number
- 99011-02-6
- Unique Ingredient Identifier
- P1QW714R7M
- Background
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and cont...
- Indication
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
- Associated Conditions
- Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
- Associated Therapies
- -
Effect of Topical Imiquimod on Lentigo Maligna
- Conditions
- First Posted Date
- 2010-07-14
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Jerry Marsden
- Target Recruit Count
- 30
- Registration Number
- NCT01161888
- Locations
- 🇬🇧
Dr J Marsden, Queen Elizabeth Hospital, Birmingham, United Kingdom
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
- Conditions
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 60
- Registration Number
- NCT01088737
- Locations
- 🇦🇹
Medical University of Graz, Graz, Austria
🇦🇹Medical University of Graz, Dept. Dermatology, Graz, Austria
Comparison of Five Treatments in Patients With Plantar Warts
- Conditions
- Interventions
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 358
- Registration Number
- NCT01059110
- Locations
- 🇫🇷
Medical center, Athis Mons, France
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2018-07-09
- Target Recruit Count
- 132
- Registration Number
- NCT00988559
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
The Effects of Aldara as an Adjunct to Laser Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Henry Vasconez
- Target Recruit Count
- 7
- Registration Number
- NCT00979550
- Locations
- 🇺🇸
University of Kentucky Division of Plastic Surgery, Lexington, Kentucky, United States
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
- Conditions
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 462
- Registration Number
- NCT00948428
- Locations
- 🇺🇸
FXM Research Corp., Miami, Florida, United States
🇺🇸University Dermatology Consultants, Inc., Cincinnati, Ohio, United States
🇺🇸Suzanne Bruce & Associates, P.A., Houston, Texas, United States
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
- Conditions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 5
- Registration Number
- NCT00941811
- Locations
- 🇦🇹
Stephan Polterauer, Vienna, Austria
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 10
- Registration Number
- NCT00899574
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT00821964
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
- Conditions
- Interventions
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00799110
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.